Articles from Ventyx Biosciences, Inc.

Ventyx Biosciences Announces Positive Topline Results from Phase 2 Study of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors

VTX3232 demonstrated significant reductions in cardiovascular risk factors, with additional benefits when combined with semaglutide

By Ventyx Biosciences, Inc. · Via GlobeNewswire · October 22, 2025